Bushido Capital US Equity ETF (SMRI)
- Expense ratio0.68%
- Net assets$749.9M
- Dividend yield1.49%
- 1-year return+38.50%
- Holdings51
SMRI ETF price chart
SMRI quote & trading statistics
SMRI performance
Annual returns & drawdowns →- YTD+33.50%
- 1 year+38.50%
- 3 years+26.52%/yr
- 1Y volatility
- 19.29%
- 3Y volatility
- 15.71%
- 3Y Sharpe ratio
- 1.15
Returns include reinvested distributions; 3-, 5- and 10-year figures are annualized.
SMRI top 10 holdings
All holdings →| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ACN | Accenture plc | 2.74% |
| 2 | CTSH | Cognizant Technology Solutions Corp Class A | 2.43% |
| 3 | ADSK | Autodesk Inc | 2.35% |
| 4 | INTU | Intuit Inc | 2.35% |
| 5 | UTHR | United Therapeutics Corporation | 2.19% |
| 6 | MPC | Marathon Petroleum Corp | 2.16% |
| 7 | CI | Cigna Corp | 2.12% |
| 8 | CNC | Centene Corp | 2.12% |
| 9 | ZTS | Zoetis Inc | 2.12% |
| 10 | MCK | McKesson Corporation | 2.10% |
The top 10 holdings make up 22.7% of the fund (51 holdings in total). As of October 24, 2026.
About Bushido Capital US Equity ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of the fund"s net assets (plus the amount of any borrowings for investment purposes) in U.S. listed common stock.
SMRI ETF FAQ
What is the SMRI expense ratio?
Bushido Capital US Equity ETF has a net expense ratio of 0.68%, or $68.00 a year for every $10,000 invested.
How much money is in SMRI?
Bushido Capital US Equity ETF has about $749.9M in net assets.
What are the top holdings of SMRI?
The largest positions in SMRI are Accenture plc (2.74%), Cognizant Technology Solutions Corp Class A (2.43%), Autodesk Inc (2.35%). The fund holds 51 securities in total.
How has SMRI performed?
SMRI returned +38.50% over the past year, including reinvested distributions.
Does SMRI pay dividends?
SMRI has a dividend yield of 1.49%.
When was SMRI launched?
Bushido Capital US Equity ETF began trading on September 13, 2023.